Skip to main content
TipRanks
Go Ultimate75% OFF

Cannabix Technologies (BLO) AI Stock Analysis

68 Followers
TSE:BLO

Cannabix Technologies

(CNQX:BLO)

Select Model
Rating:46Neutral
Price Target:CAD 0.36â–¼(-1.89% Downside)
Action:upgraded
Date:10/22/26

The overall score is severely constrained by the company's dire financial position, which is the most significant factor. Cannabix has no revenue, widening losses, and a rapidly shrinking asset base, indicating a critical need for external financing. While short-term technicals show some positive momentum, this is a secondary factor that does not offset the fundamental risk. The negative P/E ratio confirms the lack of earnings, making the stock a highly speculative investment.

Positive Factors
Low LeverageVery low leverage limits solvency pressure and reduces the immediate burden of interest and refinancing obligations. This gives Cannabix more flexibility to pursue development activities without the balance-sheet constraints typically associated with heavily debt-funded businesses.
Negative Factors
Minimal Commercial RevenueThe absence of meaningful revenue shows that Cannabix has not yet demonstrated commercial scale or recurring customer monetization. Without an established revenue base, funding for development and operations remains dependent on future financing or successful product commercialization.

Cannabix Technologies (BLO) vs. iShares MSCI Canada ETF (EWC)

-50%-25%0%25%50%75%TSE:BLO-30.19%EWC+11.69%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 32.59M
Dividend Yield
―
Average Volume (3M)
32.34K
Price to Earnings (P/E)
-11.8
Beta (1Y)
-0.14
Revenue Growth
―
EPS Growth
-84.43%
Country
Canada
Employees
0
Sector
Healthcare
Sector Strength
51
Industry
Other Precious Metals

Cannabix Technologies Business Overview & Revenue Model

Company Description

Cannabix Technologies Inc., a technology company, develops marijuana and alcohol breathalyzer technologies for employers, law enforcement, workplaces, and laboratories in the United States. It offers Cannabix Marijuana Breath Test (MBT) for Tetrahydr...

Cannabix Technologies Financial Statement Overview

Summary

Cannabix Technologies is a pre-revenue company with no sales and escalating net losses, reaching -$5.8M annually. The balance sheet shows rapidly eroding equity and assets, while cash flow is entirely negative with a short cash runway. Overall financial health is extremely poor, posing an existential risk without new funding.

Income Statement

1Very Negative

Balance Sheet

25Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMJul 2026Jul 2025Jul 2024Jul 2023Jul 2022
Income Statement
Total Revenue-100000
Gross Profit-261.54K-172.97K-168.52K-153.24K-126.29K-29.22K
EBITDA-5.73M-5.83M-4.42M-2.96M-2.01M-3.11M
Net Income-5.76M-5.76M-4.69M-3.13M-2.14M-3.37M
Balance Sheet
Total Assets2.21M2.21M3.00M4.70M6.95M8.76M
Cash, Cash Equivalents and Short-Term Investments1.59M1.59M2.35M4.26M6.52M8.45M
Total Debt160.06K160.06K158.65K154.58K132.54K0
Total Liabilities431.71K431.71K447.71K248.02K237.17K120.84K
Stockholders Equity1.78M1.78M2.55M4.45M6.71M8.64M
Cash Flow
Free Cash Flow-1.74M-1.74M-1.86M-2.11M-2.00M-2.13M
Operating Cash Flow-1.74M-1.74M-1.84M-2.08M-1.97M-2.13M
Investing Cash Flow00-17.54K-30.96K-28.65K-4,592
Financing Cash Flow968.26K968.26K-58.47K-143.53K10.88K492.50K

Cannabix Technologies Technical Analysis

Technical Analysis SentimentNegative
Last Price0.37

Price Trends

50DMA0.39Negative
100DMA0.46Negative
200DMA0.56Negative

Market Momentum

MACD-0.01Positive
RSI46.01Neutral
STOCH33.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLO, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.39, and below the 200-day MA of 0.56, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 46.01 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BLO.

Cannabix Technologies Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:BLO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:BLOTSE:BLO46NeutralCAD 45.58M-11.79-232.36%――-84.43%
TSE:PINKTSE:PINK44NeutralCAD 20.71M-1.03-303.05%―35.27%58.34%
TSE:VPTTSE:VPT39UnderperformCAD 13.50M-5.3656.40%―89.06%37.62%

* Healthcare Sector Average

Performance Comparison

0%100%200%TSE:BLOTSE:PINKTSE:VPTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:BLO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:BLOCannabix0.37-0.18-32.73%
TSE:PINKPerimeter Medical Imaging Ai Inc0.14-0.04-25.00%
TSE:VPTVentriPoint Diagnostics0.07-0.02-22.22%

Cannabix Technologies Corporate Events

Business Operations and StrategyProduct-Related Announcements

Cannabix Reports Fentanyl Detection in Human Breath

Positive
Nov 9, 2026

Cannabix Technologies reported detecting fentanyl in human breath samples collected with its Breath Collection Unit and disposable Breath Cartridges, then confirmed by Omega Laboratories using liquid chromatography-mass spectrometry. Because fentanyl...

Business Operations and StrategyProduct-Related Announcements

Cannabix launches DOT-like breath-based multi-drug test panel for recent-use detection

Positive
Oct 20, 2026

Cannabix Technologies Inc., a Vancouver-based developer of breath-based marijuana and alcohol testing solutions, focuses on non-invasive tools that enhance public and workplace safety by identifying recent impairment rather than historical drug use....

Business Operations and StrategyProduct-Related Announcements

Cannabix Files Patent for Rapid Point-of-Care Marijuana Breath Test

Positive
Oct 14, 2026

Cannabix Technologies has filed a U.S. provisional patent application for a rapid, point-of-care marijuana breath test that combines its proprietary Breath Collection Unit and Breath Cartridge with lateral flow assay platforms. The proposed system is...

Business Operations and StrategyProduct-Related Announcements

Cannabix’s BreathLogix Enters U.S. Manufacturing Market with Alabama Deployment

Positive
Sep 29, 2026

Cannabix Technologies has deployed its BreathLogix alcohol screening solution at a manufacturing facility in Alabama, marking the product’s first delivery to a U.S.-based manufacturing company. The system, distributed through reseller AlcoPro, will s...

Business Operations and StrategyProduct-Related Announcements

Cannabix Expands BreathLogix Alcohol Monitoring Deployment in Montana

Positive
Aug 21, 2026

Cannabix Technologies has deployed its BreathLogix alcohol screening system at the Big Horn County Misdemeanor Probation and Pre-trial Services department in Montana, expanding its footprint under the state’s 24/7 Sobriety Program. The device, instal...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 22, 2026